Quick answer · /answers/ cluster · Regulatory status
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is prepared by licensed compounding pharmacies and is not an FDA-approved product — approval belongs to Zepbound and Mounjaro, the brand products whose clinical trials (the ~20%-class SURMOUNT results) generated the evidence. Since the FDA declared the tirzepatide shortage resolved in December 2024, compounded versions are generally prepared under 503A patient-specific prescriptions rather than bulk production, and an April 2026 FDA proposal on compounding (91 Fed. Reg. 23431) closed comments July 30, 2026 with no final rule as of this writing. Same intended active ingredient; not the same medication; certificates stay with the brand.
What this means practically: legitimacy questions shift from “is it approved” (it isn’t) to “is the pharmacy real and the prescription patient-specific” — the verification walk in the pharmacy-check guide. Pricing context for the approved alternative: Zepbound vials from $349. Regulatory timeline in full: the prescribing-law explainer. Every compounded price on this site carries this same disclosure, by rule.